US Regulators Clear GE Healthcare's $580M Purchase of Clarient | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Federal Trade Commission has cleared the way for GE Healthcare's purchase of molecular diagnostics and imaging firm Clarient.

The FTC this week granted GE Healthcare early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, removing antitrust barriers in the US to the cash deal, estimated at $570 million to $580 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.